EMA Authorised: Daurismo (Glasdegib maleate) — Pfizer Europe MA EEIG

View source ↗

Summary

The European Medicines Agency authorized Daurismo (glasdegib) from Pfizer Europe MA EEIG for acute myeloid leukemia, with orphan medicine designation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Daurismo (glasdegib)

Snippet

Status: Authorised. Therapeutic area: Leukemia, Myeloid, Acute. MAH: Pfizer Europe MA EEIG. Decision date: 31/03/2025. Orphan medicine